Cargando…

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland

BACKGROUND: Causative variants in BRCA1 and BRCA2 are well-established risk factors for breast and ovarian cancer. In Poland, the causative founder variants in the BRCA1 are responsible for a significant proportion of ovarian cancer cases, however, regional differences in the frequencies of various...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kluz, Tomasz, Jasiewicz, Andrzej, Marczyk, Elżbieta, Jach, Robert, Jakubowska, Anna, Lubiński, Jan, Narod, Steven A., Gronwald, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828315/ https://www.ncbi.nlm.nih.gov/pubmed/29492181 http://dx.doi.org/10.1186/s13053-018-0089-x

Ejemplares similares

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2022)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
por: Wojcik, P., et al.
Publicado: (2016)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
por: Byrski, Tomasz, et al.
Publicado: (2012)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
por: Ławniczak, Małgorzata, et al.
Publicado: (2016)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone
por: Galor, Anna, et al.
Publicado: (2013)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
por: Jakubowska, Anna, et al.
Publicado: (2008)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

Evidence of a founder BRCA1 mutation in Scotland
por: Liede, A, et al.
Publicado: (2000)

Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
por: Ertmański, S, et al.
Publicado: (2012)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Founder BRCA1 mutations in Nepalese population
por: Mehta, Anurag, et al.
Publicado: (2022)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study
por: Iqbal, Javaid, et al.
Publicado: (2016)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers
por: Marciniak, Wojciech, et al.
Publicado: (2021)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Looking for BRCA1 and BRCA2 mutations in Asian women with breast cancer
por: Narod, Steven A.
Publicado: (2023)

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population
por: Belanger, Moria H, et al.
Publicado: (2015)

Selected aspects of genetic counselling for BRCA1 mutation carriers
por: Gronwald, Jacek
Publicado: (2007)

Survival from breast cancer in women with a BRCA2 mutation by treatment
por: Evans, D. Gareth, et al.
Publicado: (2021)

A common missense variant in BRCA2 predisposes to early onset breast cancer
por: Górski, Bohdan, et al.
Publicado: (2005)

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
por: Phelan, C M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kg3mh1knt07kvbd3bo26dg8rnl